Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

July 12, 2018 updated by: Memorial Sloan Kettering Cancer Center

Endothelial Dysfunction in Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events

The purpose of this study is to look at a new method for finding out if patients have a risk of heart complications from surgery. At the present, to find out if patients have a risk of heart complications from surgery, look at whether the patient has heart disease, diabetes, kidney problems, and stroke. The investigators hope that this study will confirm a new, safe test to help us predict the risk of surgery.

Study Overview

Study Type

Observational

Enrollment (Actual)

67

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients scheduled for major intrathoracic or intraabdominal surgery who meet inclusion criteria and are seen either in preoperative cardiology consultation or by another pre-surgical service such as general medicine will be eligible for screening.

Description

Inclusion Criteria:

  • Age 50 or older
  • Undergoing High Risk Cancer Surgery (Patient must be undergoing one of the following procedures NOTE: All open or robotic forms of the following procedures meet the eligibility criteria. GMT/ Hepatobiliary
  • Pancreatic Resection
  • Retroperitoneal Sarcomas
  • Shoulder (Forequarter) Amputation
  • Esophagectomy, Esophagogastrectomy
  • Pheochromocytoma
  • Liver Resection (with or without Bile Duct Resection) Orthopedics
  • Spine Resections (with or without Spinal Fusion)
  • Metastatic Disease Requiring Total Hip Replacement
  • Total Shoulder Replacement / Forequarter Amputation
  • Hemipelvectomy
  • Sacrectomy Thoracic
  • Extrapleural Pneumonectomy
  • Pleurectomy and Decortication
  • Pneumonectomy
  • Esophagogastrectomy
  • Mediastinal Tumor Resection
  • Pancoast Tumor
  • Completion Pneumonectomy
  • Lobectomy (post-induction chemotherapy; or severe COPD)
  • Segmentectomy Colorectal/ GYN
  • Colon Resection with possible Sacrectomy
  • Pelvic Exenteration
  • Advanced ovarian cancer resection with or without liver resection Urology
  • Radical Cystectomy
  • Open Radical Prostatectomy
  • Nephrectomy with Vena Caval Resection Head & Neck
  • Thyroid Resection with Mediastinal involvement
  • Major head and neck cancer resection with Free Flap reconstruction Other
  • Unclassified Major Surgery at the Discretion of the PI
  • Postoperative stay likely to be 2 or more days
  • Patients willing to tolerate inflation of a blood pressure cuff for 5 minutes
  • Patients willing to cut long nails in order to wear finger probe.
  • Patients with one or more of the following RCRI risk factors:
  • History of ischemic heart disease (any)
  • History of myocardial infarction
  • History of positive exercise test
  • Current complaint of chest pain considered secondary to myocardial ischemia
  • Use of nitrate therapy
  • ECG with pathological Q waves
  • History of congestive heart failure (any)
  • History of congestive heart failure
  • Pulmonary edema
  • Paroxysmal nocturnal dyspnea
  • Bilateral rales or S3 gallop
  • Chest radiograph showing pulmonary vascular redistribution
  • History of cerebrovascular disease (any)
  • History of transient ischemic attack (TIA) or stroke
  • Preoperative treatment with insulin
  • Preoperative serum creatinine > 2.0 mg/dL
  • Evidence of peripheral vascular disease other than cerebral vascular disease (Although peripheral vascular disease is not strictly a RCRI risk factor, Fleisher indicates: "It would not be inappropriate to assume that any atherosclerotic class of disease is equivalent to ischemic heart disease for risk purposes."

Exclusion Criteria:

  • Medical conditions precluding use of arm blood pressure measurements such as prior lymphadenectomy, vascular shunts for dialysis or upper extremity occlusive vascular disease
  • Patients undergoing emergency surgery
  • Any of the following active conditions
  • Unstable coronary syndromes
  • Uncompensated heart failure; worsening or new onset CHF
  • Significant arrhythmias
  • Atrial fibrillation, presently
  • High grade AV block
  • Symptomatic ventricular arrhythmias or new ventricular arrhythmias
  • Supraventricular arrhythmias with poor rate control
  • Symptomatic bradycardia
  • Severe valvular disease
  • Severe aortic stenosis (mean transvalvular gradient >40mmHg)
  • Symptomatic mitral stenosis
  • Any other condition that at the judgment of the investigator might require additional evaluation and treatment before surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
pts undergoing major surg procedure referred to cardiology
Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To determine whether endothelial dysfunction as measured by abnormal flow mediated dilation (FMD).
Time Frame: 1 year
Identifies patients at high risk of cardiovascular complications after major thoracic or abdominal cancer surgery.
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To obtain preliminary information on whether abnormal FMD adds predictive information beyond risk algorithms
Time Frame: 1 year
proposed by the American Heart Association/American College of Cardiology.
1 year
To determine whether abnormal flow mediated dilation (FMD) correlates to abnormal brain natriuretic enzyme BNP levels prior to surgery.
Time Frame: 1 year
1 year
To survey whether FMD prior to surgery is affected by treatment with chemotherapy and/or radiation prior to major cancer surgery
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Baum, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

July 11, 2018

Study Completion (Actual)

July 11, 2018

Study Registration Dates

First Submitted

December 15, 2010

First Submitted That Met QC Criteria

December 16, 2010

First Posted (Estimate)

December 17, 2010

Study Record Updates

Last Update Posted (Actual)

July 13, 2018

Last Update Submitted That Met QC Criteria

July 12, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on High Risk for Postoperative Cardiovascular Events

Clinical Trials on endothelial function testing

3
Subscribe